Showing 2171-2180 of 5623 results for "".
- Researchers Detail How Neurons Build a 3-D Vascular Structure to Keep the Retina Healthyhttps://modernod.com/news/researchers-detail-how-neurons-build-a-3-d-vascular-structure-to-keep-the-retina-healthy/2482292/Scientists have known for years that a lattice of blood vessels nourishes cells in the retina that allow us to see – but it’s been a mystery how the intricate structure is created. Now, researchers at University of California San Francisco have found a new type of neuron that guides i
- Topcon Healthcare Partners with Microsoft to Deliver AI-Powered ‘Healthcare from the Eye’https://modernod.com/news/topcon-healthcare-partners-with-microsoft-to-deliver-ai-powered-healthcare-from-the-eye/2482274/Topcon Healthcare announced a partnership with Microsoft Corporation to deliver AI-powered ‘Healthcare from the Eye’ solutions to improve healthcare access, cost, and quality. A cloud-based connected network of healthcare providers using the 'Nuance Precision I
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgeryhttps://modernod.com/news/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-for-the-treatment-of-decreased-va-under-low-light-conditions-following-keratorefractive-surgery/2482227/Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 phase 3 registration study evaluating phentolamine ophthalmic solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery. The LY
- Oculis Appoints Snehal Shah, PharmD, as President of Research & Developmenthttps://modernod.com/news/oculis-appoints-snehal-shah-pharmd-as-president-of-research-development/2482225/Oculis announced the appointment of Snehal Shah, PharmD, executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D. In this new role, Dr. Shah will be responsible for leading research and developmen
- Nidek Announces Winners of the 4th Annual Image of the Year Awardhttps://modernod.com/news/nidek-announces-winners-of-the-4th-annual-image-of-the-year-award/2482217/Nidek has announced the winners of the 4th annual 'Image of the Year' Award. With the contest theme, "invisible to visible," this year featured diabetic retinopathy (DR) cases which often require examination of the fovea to the extreme periphery. Eye care pr
- New VR Solution Aims to Democratize Ophthalmic Surgical Traininghttps://modernod.com/news/new-vr-solution-aims-to-democratize-ophthalmic-surgical-training/2482216/At the ASCRS annual meeting in Boston, Orbis International and FundamentalVR launched a new immersive virtual reality (VR) training solution designed for use in low- and middle-income countries. The tool is built to support students and residents learning to perform surgery to trea
- Sight Sciences Announces the Results of the 3-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCThttps://modernod.com/news/sight-sciences-announces-the-results-of-the-3-year-prospective-gemini-trial-and-the-cross-over-phase-of-the-sahara-rct/2482205/Sight Sciences announced that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System, will be presented in two oral presentations and two posters at this year’s ASCRS annual meeting, April 5-8, 
- Alcon to Highlight New Data at ASCRS Demonstrating Innovations Designed to Optimize Patient Outcomeshttps://modernod.com/news/alcon-to-highlight-new-data-at-ascrs-demonstrating-innovations-designed-to-optimize-patient-outcomes/2482199/Alcon will showcase approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 5-8, in Boston. In additio
- Melt Pharmaceuticals Completes Stock Refinancing to Support Further Development of MELT-300https://modernod.com/news/melt-pharmaceuticals-completes-stock-refinancing-to-support-further-development-of-melt-300/2482198/Melt Pharmaceuticals announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors. The capital raised will primarily support the further development of MELT-300, including the MELT-300 phase 3 program. MELT-300, a n
- Cliara Awarded US Patent for Contact Lens Force Measurement Devicehttps://modernod.com/news/cliara-awarded-us-patent-for-contact-lens-force-measurement-device/2482179/Cliara has been granted a United States patent for a device designed to accurately measure the force required to remove gas-permeable contact lenses from the eye, according to a company news release. Cliara LLC is collaborating with BostonSight and LV Prasad Eye Institute